Group items tagged

Wednesday, November 19, 2008 The Fructose Index is the New Glycemic Index I stumbled upon an interesting editorial recently in the American Journal of Clinical Nutrition from Dr. Richard Johnson's group, entitled "How Safe is Fructose for Persons With or Without Diabetes?" It was a response to a meta-analysis in the same journal pronouncing fructose safe up to 90 grams per day. That's the amount in eight apples or four cans of soda. Not quite what our hunter-gatherer ancestors were eating! The editorial outlined the case against excessive fructose, which I feel is quite strong. That led me to another, more comprehensive paper from Dr. Johnson's group, which argues that the amount of fructose found in a food, which they call the "fructose index", is more relevant to health than the food's glycemic index.

JAMA editorial

Since its launch in 2003, Nutrition Data has grown into one of the most authoritative and useful sources of nutritional analysis on the Web. In July 2006, Nutrition Data was acquired by CondéNet, a digital publisher under the Condé Nast Publications umbrella dedicated to editorial excellence. Nutrition Data's continuing goal is to provide the most accurate and comprehensive nutrition analysis available, and to make it accessible and understandable to all.\nThe information in Nutrition Data's database comes from the USDA's National Nutrient Database for Standard Reference and is supplemented by listings provided by restaurants and food manufacturers.

WebMD provides valuable health information, tools for managing your health, and support to those who seek information.\n\nThe WebMD content staff blends award-winning expertise in medicine, journalism, health communication and content creation to bring you the best health information possible. Our esteemed colleagues at MedicineNet.com are frequent contributors to WebMD and comprise our Medical Editorial Board

"Largest-ever meta-analysis finds CRP is unlikely to be causal for CVD December 21, 2009 | Lisa Nainggolan Cambridge, UK - In the largest and most comprehensive meta-analysis to date looking at C-reactive-protein (CRP) levels and risk of coronary heart disease (CHD) and stroke, British researchers conclude that CRP is unlikely to be a causal factor for cardiovascular disease [1]. Although CRP concentration was linearly associated with CHD, stroke, and vascular mortality, as well as nonvascular mortality, statistical adjustment for conventional cardiovascular risk factors "resulted in considerable weakening of associations," note the scientists of the Cambridge-based Emerging Risk Factors Collaboration (ERFC), who report their findings online December 21, 2009 in the Lancet. In an editorial accompanying the paper [2], Drs S Matthijs Boekholdt and John JP Kastelein (Academic Medical Center, Amsterdam, the Netherlands) say the UK authors "are to be commended for this impressive data set." Although the findings "add weight to the evidence of noncausality" for a role of CRP in the development of cardiovascular disease, "the debate can be resolved only by randomized trials with agents that specifically target CRP, and such compounds are currently under development," say the Dutch doctors. Commenting on the new meta-analysis for heartwire, Dr Paul Ridker (Brigham and Women's Hospital, Boston, MA), a long-time advocate of CRP and the lead investigator of the JUPITER trial, said: "Whether or not CRP is 'causal' for heart disease is neither the crucial issue at hand nor relevant for public health. What is crucial is getting international agreement that CRP identifies higher-risk individuals who would not otherwise qualify for a life-saving therapy, and then showing that such individuals clearly benefit from treatment. The new meta-analysis demonstrates the former, and JUPITER demonstrates the latter." "

"Vytorin has struck out again, this time in a clinical trial that compared the drug's safety and efficacy to a prescription form of the B vitamin niacin. The results of the trial, which the New England Journal of Medicine featured in an article and two editorials, were presented Sunday at an American Heart Association meeting and showed that in a direct comparison, niacin worked significantly better than Vytorin and Zetia in reducing arterial blockages. According to a report in NPR, "This study is the third to question whether ezetimibe drugs do what they're supposed to." If lowering LDL or "bad" cholesterol is the doctor's sole intention when prescribing Vytorin to patients, then the drug does a great job. However, as previous studies have shown, lower levels of LDL cholesterol don't automatically translate to cleaner arteries and lower incidences of cardiac arrest. While Vytorin worked better than statins combined with time-release Niacin to lower LDL cholesterol in 200 patients, its performance was inferior in reducing artery clogging deposits."

"For what reason I don't know, but this January 2009 editorial by William Faloon of the Life Extension Foundation is making the rounds. Perhaps it just came available on the web. It's a good read, particularly in light of the billions and trillions of dollars the thieves & thugs in DC are about to flush down the crapper on your behalf. Some notable excerpts. A large number of new vitamin D studies have appeared in the scientific literature since I wrote my plea to the federal government. These studies don't just confirm what we knew 16 months ago-they show that optimizing vitamin D intake will save even more lives than what we projected. For instance, a study published in June 2008 showed that men with low vitamin D levels suffer 2.42 times more heart attacks. Now look what this means in actual body counts. Each year, about 157,000 Americans die from coronary artery disease-related heart attacks. Based on this most recent study, if every American optimized their vitamin D status, the number of deaths prevented from this kind of heart attack would be 92,500. To put the number of lives saved in context, tens of millions of dollars are being spent to advertise that Lipitor® reduces heart attacks by 37%. This is certainly a decent number, but not when compared with how many lives could be saved by vitamin D. According to the latest study, men with the higher vitamin D levels had a 142% reduction in heart attacks."

"July 9, 2008 | Michael O'Riordan Boston, MA - The consumption of a diet containing vegetable oils rich in alpha-linolenic acid (ALA) is associated with significant reductions in the risk of nonfatal MI, a new study has shown [1]. Investigators say the protective effect of ALA is evident among individuals with low intakes, suggesting the greatest benefit might be in developing countries, where fatty-acid consumption is limited. "The potential for benefit is great when the baseline intake is low," said lead investigator Dr Hannia Campos (Harvard Medical School, Boston, MA). "In countries where people eat very little fish-and some of these countries have almost no sources of omega-3 fatty acids because they cook with corn or sunflower oils-the consumption of vegetable oils with ALA could have a major impact on heart disease." In an editorial accompanying the published study [2], Dr William Harris (University of South Dakota, Sioux Falls) said that the data are suggestive and would be good news for individuals who will not or cannot eat fish, but more studies are still needed. "If ALA were able to do the same 'heavy lifting' that [eicosapentaenoic acid] EPA and [docosahexaenoic acid] DHA do, this would be welcomed news, because the capacity to produce ALA is essentially limitless, whereas there are only so many fish in the sea," he writes. "

Ikaria Lean Belly Juice Only $69/Bottle Limited Time Offer! Special Deal + Special 80% Discount Save $840+ 180 Days Money Back Guarantee lkaria Lean Belly Juice lkaria Lean Belly Juice Five Star Ikaria Lean Belly Juice is a powerful new formula that makes weight loss easier, faster and much more fun… Ikaria Lean Belly Juice is a powerful weight management complex that is 100% herbal and pure, which can aid in burning stubborn belly fat effectively and helps you lose weight naturally. Regular Price: $179/per bottle Only for: $69/per bottle Buy Now What Is Ikaria Lean Belly Juice? Ikaria Lean Belly Juice formula is different from other weight loss or diet pills. You might have never tried or seen something like or even close. Ikaria Lean Belly Juice for losing belly fat before. As the name suggests, this Ikaria belly fat-burning juice is based on a daily ritual of the healthiest part of the world, Ikaria. Researchers found that a number of natural ingredients, fruits, and plant extracts available on the island can help lose weight by eliminating toxic lipid molecules and reducing high uric acid levels in the human body. Ikaria Lean Belly Juice is an effective weight loss diet supplement that is made up of several effective, scientifically-proven ingredients that can help you lose weight. It aids in shedding belly fat and excess weight. This product has incredible health benefits to clients. The Ikaria Lean Belly Juice formula was created by a group of experts who wanted to help all those people who were struggling to lose weight. The formula of the supplement has been prepared under strict conditions in an FDA-registered facility, and its blend of natural ingredients like milk thistle supports weight loss incredibly. Each bottle comes with 30 days of servings that can be blended together with liquids. The powder's formula is produced in GMP-certified, FDA-approved labs to guarantee high-quality and safety. A lot of people have questions rega

Vitamin K epoxide reductase complex and vascular calcification: is this the important link between vitamin K and the arterial vessel wall? Spronk HM. Circulation. 2006 Mar 28;113(12):1550-2. Review. PMID: 16567578

Leaf A.\nDietary prevention of coronary heart disease: the Lyon Diet Heart Study.\nCirculation. 1999 Feb 16;99(6):733-5.

M. F. Holick Vitamin D Deficiency: What a Pain It Is Mayo Clin. Proc., December 1, 2003; 78(12): 1457 - 1459.

Vitamin D and pancreatic cancer risk in the alpha-tocopherol, beta-carotene cancer prevention cohort. Michaud DS. Cancer Res. 2006 Oct 15;66(20):9802-3.

Vitamin D in cancer patients: above all, do no harm. Goodwin PJ. J Clin Oncol. 2009 May 1;27(13):2117-9. Epub 2009 Apr 6. PMID: 19349538

Vitamin D and autoimmune rheumatic diseases. Cutolo M. Rheumatology (Oxford). 2009 Mar;48(3):210-2. Epub 2008 Oct 17. PMID: 18930963 doi:10.1093/rheumatology/ken394

Nutrition, chronic disease, and the problem of proof. Heaney RP. Am J Clin Nutr. 2006 Sep;84(3):471-2. No abstract available. PMID: 16960157

Hunter-gatherer diets-a different perspective.\nMilton K.\nAm J Clin Nutr. 2000 Mar;71(3):665-7. Review. \nPMID: 10702155

Vitamin D, nutritional deficiency, and the medical paradigm. Heaney RP. J Clin Endocrinol Metab. 2003 Nov;88(11):5107-8. Review. No abstract available. PMID: 14602734

Expanding the orbit of primary prevention--moving beyond JUPITER. Hlatky MA. N Engl J Med. 2008 Nov 20;359(21):2280-2. Epub 2008 Nov 9. PMID: 18997195

Tofu and cognitive function: food for thought. Grodstein F, Mayeux R, Stampfer MJ. J Am Coll Nutr. 2000 Apr;19(2):207-9. Review. PMID: 10763901 In addition, a plausible biologic hypothesis is generally an important part of judging epidemiologic relations. While high tofu intake may lead to lower plasma estrogen levels [12], we do not know how tofu influences estrogen levels in the brain; we also know very little about estrogen effects in men. Furthermore, data have not even consistently indicated that low endogenous estrogen levels are directly related to cognitive function in non-demented subjects [13]. The authors also posit a non-estrogen mediated hypothesis for the effects of tofu, namely that soy inhibits hippocampal tyrosine kinase and may block long-term potentiation (the likely mechanism by which humans learn and remember). Still, considerably more work must be done to substantiate this hypothesis. Finally, the single measures of outcome used in this study may have limited value, as cognitive function and brain structure change over time. Factors which predict these measures at one point may or may not be the same as those which predict decline over time; fundamentally, the public health interest is in preventing cognitive decline, as the steepness of the decline trajectory likely provides an early marker for risk of the more clinically relevant result-dementia.